Search Results - "Wagman, R. B."

Observations following discontinuation of long-term denosumab therapy by McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., Lewiecki, E. M.

“…Summary Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not…”
Get full text

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates by Miller, P. D, Pannacciulli, N, Brown, J. P, Czerwinski, E, Nedergaard, B. S, Bolognese, M. A, Malouf, J, Bone, H. G, Reginster, J.-Y, Singer, A, Wang, C, Wagman, R. B, Cummings, S. R

“…Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the…”
Get full text

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study by Roux, C, Hofbauer, L.C, Ho, P.R, Wark, J.D, Zillikens, M.C, Fahrleitner-Pammer, A, Hawkins, F, Micaelo, M, Minisola, S, Papaioannou, N, Stone, M, Ferreira, I, Siddhanti, S, Wagman, R.B, Brown, J.P

“…Abstract Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were…”
Get full text

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial by McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.

“…Summary In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent…”
Get full text

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment by Ferrari, S, Libanati, C, Lin, Celia Jow Fang, Brown, JP, Cosman, F, Czerwiński, E, Gregόrio, LH, Malouf‐Sierra, J, Reginster, J‐Y, Wang, A, Wagman, RB, Lewiecki, EM

“…ABSTRACT Although treat‐to‐target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to reduce fracture risk…”
Get full text

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years by Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.

“…Summary Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years,…”
Get full text

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass by Kendler, D. L, Bessette, L, Hill, C. D, Gold, D. T, Horne, R, Varon, S. F, Borenstein, J, Wang, H, Man, H.-S, Wagman, R. B, Siddhanti, S, Macarios, D, Bone, H. G

“…Summary The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly…”
Get full text

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study by Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.

“…Summary The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis…”
Get full text

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover by Delmas, P.D., Licata, A.A., Reginster, J.Y., Crans, G.G., Chen, P., Misurski, D.A., Wagman, R.B., Mitlak, B.H.

“…Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk. The…”
Get full text

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate by Brown, J. P., Roux, C., Ho, P. R., Bolognese, M. A., Hall, J., Bone, H. G., Bonnick, S., van den Bergh, J. P., Ferreira, I., Dakin, P., Wagman, R. B., Recknor, C.

“…Summary Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (≥1…”
Get full text

Fracture incidence in a large cohort of men age 30 years and older with osteoporosis by Manthripragada, A. D., O’Malley, C. D., Gruntmanis, U., Hall, J. W., Wagman, R. B., Miller, P. D.

“…Summary In this large retrospective study of men with presumed osteoporosis, we estimate the rate of osteoporosis-related fractures in men age ≥30 years. Our…”
Get full text

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial by Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei‐Ran, Beck Jensen, Jens‐Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B

“…Osteoporosis is a chronic disease and requires long‐term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the…”
Get full text

Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid by Miller, P. D, Pannacciulli, N, Wagman, R. B, Cummings, S. R

Get full text

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis by Palacios, S., Kalouche-Khalil, L., Rizzoli, R., Zapalowski, C., Resch, H., Adachi, J. D., Gallagher, J. C., Feldman, R. G., Kendler, D. L., Wang, A., Wagman, R. B., Adami, S.

“…Objectives A history of prior fracture is one of the strongest predictors of a future fragility fracture. In FREEDOM, denosumab significantly reduced the risk…”
Get full text

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis by Chen, Peiqi, Satterwhite, Julie H, Licata, Angelo A, Lewiecki, E Michael, Sipos, Adrien A, Misurski, Derek M, Wagman, Rachel B

“…The relationship between early changes in biochemical markers of bone turnover and the subsequent BMD response to daily teriparatide therapy in women with…”
Get full text

P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile by Becker, C, As-Sanie, S, Zhai, D, Perry, J  S, Dynowski, K, Wilk, K, Wagman, R  B, Rakov, V  G, McClung, M  R

“…Abstract Study question How does the benefit/risk profile compare in women with endometriosis-associated pain who initiated relugolix combination therapy…”
Get full text

Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis by SILVERMAN, Stuart L, PIZIAK, Veronica K, PEIQI CHEN, MISURSKI, Derek A, WAGMAN, Rachel B

“…OBJECTIVE: To examine the association between back pain and health related quality of life (HRQOL) in postmenopausal women with osteoporosis. METHODS: The…”
Get full text

O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data by As-Sanie, S, Giudice, L, Abrao, M S, Wilk, K, Mehedintu, C, Becker, C, Arjona Ferreira, J C, Wagman, R B, Wang, F, Warsi, Q A, Neil, J

“…Abstract Study question To assess the long-term (52-week) efficacy and safety of relugolix combination therapy (Relugolix-CT) in the treatment of…”
Get full text

O-136 Once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks by Lukes, A, Venturella, R, Al-Hendy, A, Nyirady, T, Decleer, W, Petraglia, F, Li, Y, Wagman, R B, Hunsche, E, Stewart, E A

“…Abstract Study question What is the effect of relugolix combination therapy (Relugolix-CT) on symptom burden and health-related quality-of-life (HR-QoL) in…”
Get full text

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial by Brown, Jacques P, Prince, Richard L, Deal, Chad, Recker, Robert R, Kiel, Douglas P, de Gregorio, Luiz H, Hadji, Peyman, Hofbauer, Lorenz C, Álvaro‐Gracia, Jose M, Wang, Huei, Austin, Matthew, Wagman, Rachel B, Newmark, Richard, Libanati, Cesar, San Martin, Javier, Bone, Henry G

“…Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, a key mediator of osteoclast formation, function, and…”
Get full text